Periphagen

Periphagen is a biotechnology company focused on developing gene therapies for the treatment of chronic pain and other neurological disorders. The company utilizes a proprietary Herpes Simplex Virus (HSV) vector platform designed to deliver therapeutic genes directly to the peripheral nervous system. By targeting the sensory neurons that transmit pain signals, Periphagen's technology aims to provide long-lasting relief without the systemic side effects or addiction risks associated with traditional opioids. The company was acquired by Coda Biotherapeutics in 2018 to integrate its peripheral nerve targeting capabilities into Coda's chemogenetic platform.